Emmanuel Seront

2.4k total citations
74 papers, 1.3k citations indexed

About

Emmanuel Seront is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Emmanuel Seront has authored 74 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Oncology, 31 papers in Pulmonary and Respiratory Medicine and 30 papers in Surgery. Recurrent topics in Emmanuel Seront's work include Cancer Immunotherapy and Biomarkers (19 papers), Vascular Malformations and Hemangiomas (14 papers) and Bladder and Urothelial Cancer Treatments (13 papers). Emmanuel Seront is often cited by papers focused on Cancer Immunotherapy and Biomarkers (19 papers), Vascular Malformations and Hemangiomas (14 papers) and Bladder and Urothelial Cancer Treatments (13 papers). Emmanuel Seront collaborates with scholars based in Belgium, France and United States. Emmanuel Seront's co-authors include Miikka Vikkula, Laurence M. Boon, An Van Damme, Olivier Féron, Angela Queisser, Jean‐Pascal Machiels, Caroline Bouzin, Sophie Dupont, Jennifer Hammer and Sandra Schmitz and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Circulation Research.

In The Last Decade

Emmanuel Seront

64 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Emmanuel Seront Belgium 16 792 477 378 337 188 74 1.3k
Pramila Ramani United Kingdom 21 477 0.6× 276 0.6× 180 0.5× 533 1.6× 308 1.6× 48 1.4k
Ryuji Yasumatsu Japan 23 709 0.9× 558 1.2× 102 0.3× 221 0.7× 319 1.7× 108 1.5k
Markus Raderer Austria 20 264 0.3× 598 1.3× 328 0.9× 197 0.6× 380 2.0× 62 1.5k
Zhen Huang China 18 321 0.4× 480 1.0× 152 0.4× 249 0.7× 267 1.4× 104 1.2k
Mirella Marino Italy 25 420 0.5× 398 0.8× 1.7k 4.4× 168 0.5× 181 1.0× 82 2.3k
Yosuke Yamakawa Japan 21 310 0.4× 347 0.7× 425 1.1× 574 1.7× 318 1.7× 96 1.5k
Daniel Chubb Australia 21 669 0.8× 308 0.6× 72 0.2× 512 1.5× 265 1.4× 48 1.8k
Anuhya Kommalapati United States 18 373 0.5× 603 1.3× 66 0.2× 305 0.9× 254 1.4× 63 1.1k
Beate Häberle Germany 18 336 0.4× 254 0.5× 221 0.6× 486 1.4× 71 0.4× 42 1.1k
Shiu-Feng Huang Taiwan 20 431 0.5× 339 0.7× 67 0.2× 241 0.7× 292 1.6× 42 1.1k

Countries citing papers authored by Emmanuel Seront

Since Specialization
Citations

This map shows the geographic impact of Emmanuel Seront's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emmanuel Seront with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emmanuel Seront more than expected).

Fields of papers citing papers by Emmanuel Seront

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emmanuel Seront. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emmanuel Seront. The network helps show where Emmanuel Seront may publish in the future.

Co-authorship network of co-authors of Emmanuel Seront

This figure shows the co-authorship network connecting the top 25 collaborators of Emmanuel Seront. A scholar is included among the top collaborators of Emmanuel Seront based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emmanuel Seront. Emmanuel Seront is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Seront, Emmanuel, et al.. (2025). Personalized sirolimus regimen for vascular malformations: a retrospective analysis of VASE cohort. Orphanet Journal of Rare Diseases. 21(1). 62–62.
2.
Seront, Emmanuel, Karolien Goffin, Anne-Sophie Govaerts, et al.. (2025). Efficacy of [177Lu]Lu-PSMA-617 in Patients with Metastatic Clear-cell Renal Cell Carcinoma: The Multicentre, Single-arm, Phase 2 RENALUT Trial. European Urology Oncology. 8(6). 1592–1597.
3.
Gheysens, Olivier, et al.. (2024). Bilateral intense [68 Ga]Ga-PSMA‑11 uptake in cyproterone acetate induced gynecomastia. European Journal of Nuclear Medicine and Molecular Imaging. 52(6). 1937–1938.
4.
Seront, Emmanuel, Cédric Hermans, Laurence M. Boon, & Miikka Vikkula. (2024). Targeted treatments for vascular malformations: current state of the art. Journal of Thrombosis and Haemostasis. 22(11). 2961–2975. 9 indexed citations
5.
Seront, Emmanuel, et al.. (2024). Neurological Adverse Events Related to Immune Checkpoint Inhibitors: A Practical Review. Pharmaceuticals. 17(4). 501–501. 10 indexed citations
6.
Seront, Emmanuel, et al.. (2024). Systemic Treatments for Metastatic Prostate Cancer in 2024. European Urology Focus. 10(4). 522–524. 3 indexed citations
7.
Seront, Emmanuel, An Van Damme, Nicole Revençu, et al.. (2023). A case report of sirolimus use in early fetal management of lymphatic malformation. Nature Cardiovascular Research. 2(6). 595–599. 14 indexed citations
8.
Seront, Emmanuel, An Van Damme, Catherine Legrand, et al.. (2023). Preliminary results of the European multicentric phase III trial regarding sirolimus in slow-flow vascular malformations. JCI Insight. 8(21). 28 indexed citations
9.
Monteiro, Fernando Sabino Marques, Ondřej Fiala, Francesco Massari, et al.. (2023). Systemic Immune-Inflammation Index in Patients Treated With First-Line Immune Combinations for Metastatic Renal Cell Carcinoma: Insights From the ARON-1 Study. Clinical Genitourinary Cancer. 22(2). 305–314.e3. 4 indexed citations
10.
Seront, Emmanuel, et al.. (2022). Global management of brain metastasis from renal cell carcinoma. Critical Reviews in Oncology/Hematology. 171. 103600–103600. 4 indexed citations
11.
Duhoux, François P., et al.. (2022). Radium-223 as an Additional Therapeutic Strategy in Highly Selected Patients With Metastatic Breast Cancer: A Case Report. Frontiers in Oncology. 12. 896301–896301. 1 indexed citations
12.
Queisser, Angela, Emmanuel Seront, Laurence M. Boon, & Miikka Vikkula. (2021). Genetic Basis and Therapies for Vascular Anomalies. Circulation Research. 129(1). 155–173. 120 indexed citations
13.
Chanzá, Nieves Martínez, Philippe Barthélémy, Thierry Gil, et al.. (2021). Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial). BMC Cancer. 21(1). 1292–1292. 12 indexed citations
14.
Seront, Emmanuel, et al.. (2020). Theranostic Advances in Vascular Malformations. Journal of Investigative Dermatology. 140(4). 756–763. 42 indexed citations
15.
Damme, An Van, et al.. (2020). New and Emerging Targeted Therapies for Vascular Malformations. American Journal of Clinical Dermatology. 21(5). 657–668. 67 indexed citations
16.
Petit, B., et al.. (2020). c-MET as a Potential Resistance Mechanism to Everolimus in Breast Cancer: From a Case Report to Patient Cohort Analysis. Targeted Oncology. 15(1). 139–146. 7 indexed citations
17.
Seront, Emmanuel, Nisha Limaye, Laurence M. Boon, & Miikka Vikkula. (2016). La rapamycine ouvre l’ère des thérapies ciblées dans les malformations veineuses. médecine/sciences. 32(6-7). 574–578. 2 indexed citations
18.
Seront, Emmanuel, Sandra Schmitz, Sylvie Rottey, et al.. (2016). Phase I study of ribociclib plus cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Annals of Oncology. 27. vi345–vi345. 3 indexed citations
19.
Draoui, Nihed, Emmanuel Seront, Caroline Bouzin, et al.. (2014). Antitumor Activity of 7-Aminocarboxycoumarin Derivatives, a New Class of Potent Inhibitors of Lactate Influx but Not Efflux. Molecular Cancer Therapeutics. 13(6). 1410–1418. 96 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Pramila Ramani Breakdown of academic impact, for papers by Ryuji Yasumatsu Breakdown of academic impact, for papers by Markus Raderer Breakdown of academic impact, for papers by Zhen Huang Breakdown of academic impact, for papers by Mirella Marino Breakdown of academic impact, for papers by Yosuke Yamakawa Breakdown of academic impact, for papers by Daniel Chubb Breakdown of academic impact, for papers by Anuhya Kommalapati Breakdown of academic impact, for papers by Beate Häberle Breakdown of academic impact, for papers by Shiu-Feng Huang
Rankless by CCL
2026